

Oncology Today with Dr Neil Love: First-Line and Maintenance Therapy for Patients with HER2-Positive Metastatic Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. According to blinded independent central review in the Phase III DESTINY-Breast09 trial, what was the approximate reduction in risk of disease progression or death with trastuzumab deruxtecan (T-DXd) and pertuzumab in comparison to taxane/trastuzumab/pertuzumab (THP) as first-line therapy for patients with advanced HER2-positive breast cancer?
 - a. 10%
 - b. 24%
 - c. 44%
 - d. 62%
2. Which of the following statements best characterizes the confirmed objective response rate (cORR) for patients with and without a PIK3CA mutation who received T-DXd and pertuzumab versus THP in the DESTINY-Breast09 trial?
 - a. cORR favored T-DXd and pertuzumab for only those patients with PIK3CA wild-type breast cancer
 - b. cORR favored T-DXd and pertuzumab for only those patients with PIK3CA-mutant breast cancer
 - c. cORR favored T-DXd and pertuzumab regardless of PIK3CA mutation status
3. Which of the following outcomes was observed in the Phase III PATINA trial evaluating the addition of palbociclib to maintenance anti-HER2 and endocrine therapy after induction treatment for hormone receptor-positive, HER2-positive metastatic breast cancer?
 - a. The addition of palbociclib resulted in a significant improvement in progression-free survival (PFS) and overall survival (OS)
 - b. The addition of palbociclib resulted in a significant improvement in PFS and a numerically positive trend for OS
 - c. The addition of palbociclib did not result in significant improvement in PFS or OS
4. In the DESTINY-Breast09 trial, what proportion of patients receiving T-DXd with pertuzumab as first-line therapy received endocrine therapy after disease progression?
 - a. 56%
 - b. 32%
 - c. 18%
 - d. 5%
5. In the HER2CLIMB-05 trial, the addition of tucatinib to trastuzumab/pertuzumab as first-line maintenance therapy improved PFS by how many months in comparison to maintenance therapy with trastuzumab/pertuzumab alone?
 - a. 2.4 months
 - b. 8.6 months
 - c. 15.1 months
 - d. 28 months